Home / Publications
"Evaluation of azacitidine in transfusion-dependent, Epo-refractory patients with lower-risk MDS". Tobiasson M, Brandefors L, Dybedahl I, Garelius H, Grovdal M et al. 17 Congress of the EHA, 2012, Abstr. nor.:1381
"Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities". Mollgard L, Saft L, Bach Treppendahl M, Dybedal I, Norgaard J M et al. Haematologica, 2011:96(7);963-971.
"Significance of JAK2 and TET2 mutations in myelodysplastic syndromes". Hellstrom-Lindberg. Blood Reviews 24(2010);83-90
"Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy". Grovdal et al. British Journal of Haematology,150;293-302
Grovdal_BJH2010.pdf 498.41 kB
"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study". Fenaux et al. LancetOncology; vol10, March2009;223-232
"Supportive care, growth factors, and new therapies in myelodysplastic syndromes". Eva Hellstrom-Lindberg, Luca Malcovati. Blood Reviews (2008)22;75–91
"Negative Effect of DNA Hypermethylation on the Outcome of Intensive Chemotherapy in Older Patients with High-Risk Myelodysplastic Syndromes and AcuteMyeloid Leukemia following Myelodysplastic Syndrome". Michael Grovdal et al. Clin Cancer Res 2007;7107-7112 13(23) December 1, 2007
"Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes". P.A. Broliden et al. Haematologica 2006;91:667-670
»» Long term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. M Jädersten, Scott M. Montgomery, Ingunn Dybedal, Anna Porwit-MacDonald and Eva Hellström-Lindberg . Clinical observations, interventions and therapeutic trials. Blood 1 August 2005.Volym 106, Number 3.
»» The WHO classification of MDS does make a difference. Robert B.Howe, Anna Porwit-McDonald,Robert Wanat, Ramin Tehranchi and Eva Hellström-Lindberg. Blood May 1 2004. Volume 103, Number 9.
»» No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease. Robert Hast et al. Leukemia 2003
Hast2003.pdf 136.57 kB
»» A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony stimulating factor: significant effects on quality of life. Eva Hellström-Lindberg et al. British Journal of Hematology, 2003
BrJH2003nmds.pdf 214.88 kB